Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

Cytokinetics IncTrade
iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.05. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

CYTKTLT
Market Cap
$10.63B
Sector
Technology
52-Week High
$87.26$92.06
52-Week Low
$34.31$82.05
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.

The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.

iShares 20 Plus Year Treasury Bond ETF

TLT (iShares 20+ Year Treasury Bond ETF) trades at $82.11, showing minimal daily movement with a 0.08% gain. The technical outlook remains bearish with moving averages signaling strong selling pressure, while oscillators indicate neutral momentum. Recent news highlights pressure from rising Treasury yields and concerns about US debt levels approaching $40 trillion, with institutional activity showing Ferguson Shapiro LLC acquiring 37,900 shares in the latest quarter.

The ETF faces headwinds from rising long-term yields and inflation concerns, though recent dividend payments provide income support. Key risks include Federal Reserve policy uncertainty and escalating geopolitical tensions affecting bond markets. Investors should monitor inflation data and Treasury yield movements for directional cues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

Read more on TLT